Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial

Author(s): Priya Rastogi, MD1,2; Hanna Bandos, PhD3,4; Peter C. Lucas, MD, PhD1; Laura J. van ‘t Veer, PhD5; Jia-Perng J. Wei, MD, PhD5; Charles E. Geyer, Jr, MD1; Louis Fehrenbacher, MD6; Stephen K.L. Chia, MD7; Adam M. Brufsky, MD, PhD1,2; Janice M. Walshe, MD8; Gamini S. Soori, MD9; Shaker R. Dakhil, MD10; Soonmyung Paik, MD11,12; Sandra M. Swain, MD13; Andrea R. Menicucci, PhD5; M. William Audeh, MD5; Norman Wolmark, MD1; Eleftherios P. Mamounas, MD14
Source: https://doi.org/10.1200/JCO.23.01995

Dr. Maen Hussein's Thoughts

MammaPrint did not predict distant recurrence, but it did predict patients who may benefit from extended hormonal therapy. We do have breast index, so now we have options. Breast index can predict the possibility of recurrence though by helping to determine the level of risk.

PURPOSE

MammaPrint (MP) determines distant metastatic risk and may improve patient selection for extended endocrine therapy (EET). This study examined MP in predicting extended letrozole therapy (ELT) benefit in patients with early-stage breast cancer (BC) from the NSABP B-42 trial.

PATIENTS AND METHODS

MP was tested in 1,866 patients randomly assigned to receive ELT or placebo. The primary end point was distant recurrence (DR). Secondary end points were disease-free survival (DFS) and BC-free interval (BCFI). Tumors were classified as MP high risk (MP-HR) or low risk (MP-LR). MP-LR tumors were further classified as ultralow risk (MP-UL) or low non-ultralow risk (MP-LNUL).

RESULTS

There was no statistically significant difference in ELT benefit on DR between MP-HR and MP-LR (interaction P = .38). MP-LR tumors (n = 1,160) exhibited a statistically significant 10-year benefit of 3.7% for DR (hazard ratio [HR], 0.43 [95% CI, 0.25 to 0.74]; P = .002), whereas MP-HR tumors (n = 706) exhibited a nonsignificant 2.4% benefit (HR, 0.65 [95% CI, 0.34 to 1.24]; P = .19). The 10-year ELT benefit was significant for DFS (7.8%) and BCFI (7.0%) for MP-LR tumors, whereas MP-HR tumors did not significantly benefit (interaction DFS: P = .015, BCFI: P = .006). In exploratory analysis, the 10-year ELT benefit was significant and more pronounced in MP-LNUL (n = 908) tumors: 4.0% for DR, 9.5% for DFS, and 7.9% for BCFI; the benefit in MP-UL (n = 252) tumors was not significant: 3% for DR, 1.8% for DFS, and 4.1% for BCFI.

CONCLUSION

The primary hypothesis of predictive ability of MP on DR was not confirmed. However, the secondary outcomes demonstrated MP was predictive of ELT response and identified a subset of patients with early-stage hormone receptor–positive BC (MP-LR) with improved outcomes from ELT. These data could have important clinical implications in patient selection beyond clinical risk assessment for EET.

Author Affiliations

1UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA; 2Magee-Women’s Hospital, Pittsburgh, PA; 3NRG Oncology SDMC, Pittsburgh, PA; 4University of Pittsburgh, School of Public Health, Pittsburgh, PA; 5Agendia, Inc, Irvine, CA; 6Kaiser Permanente Oncology Clinical Trials Northern CA, Novato, CA; 7British Columbia Cancer Agency, Vancouver, BC, Canada; 8Cancer Trials Ireland, and St Vincent’s University Hospital, Dublin, Ireland; 9Florida Cancer Specialists, Fort Myers, FL; 10Wichita NCORP, Via Christi Regional Medical Center, and Cancer Center of Kansas, Wichita, KS; 11Theragenbio, Inc, Pankyo, Republic of Korea; 12Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; 13Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; 14Advent Health Cancer Center, Orlando, FL

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116)

It seems donepezil did not show any cognitive benefit when added to standard adjuvant chemotherapy for breast cancer. Unfortunately, adequate treatment for ‘chemo-brain’ remains elusive. There is data that a lipid structure, S1P, may be linked to this process and may be ‘druggable’ with some of the MS agents.

Read More »

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Datopotamab Deruxtecan is a new ADC that will likely be approved in the near future. The payload is the same as used in Enhertu, but the antibody is directed at TROP2. This report is from the TROPION-pan tumor study and shows a promising ORR in HR+/HER2- MBC. There is reasonable data for this compound in 2L met-NSCLC in the TROPION-LUNG01 study with an improvement in PFS compared to docetaxel of 4.4 vs 3.7 months. Dato also is effective in patients with actionable genetic alterations in the 2L setting. There is also an ongoing study on its use in the 1L setting for met-NSCLC in combination with pembrolizumab and chemotherapy.

Read More »